These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 4886391)

  • 1. Uncertainty as to the acceptance or rejection of the presence of an effect in relation to the number of observations in an experiment.
    Rümke CL
    Triangle; 1968; 8(7):284-9. PubMed ID: 4886391
    [No Abstract]   [Full Text] [Related]  

  • 2. [General principles of clinical therapeutic trials].
    Sancho H
    Acta Chir Belg; 1976 Jan; 75(1):19-29. PubMed ID: 790880
    [No Abstract]   [Full Text] [Related]  

  • 3. Group sequential designs for clinical trials.
    Elfring GL; Schultz JR
    Biometrics; 1973 Sep; 29(3):471-7. PubMed ID: 4599229
    [No Abstract]   [Full Text] [Related]  

  • 4. Change the rules for clinical trials in general practice.
    Lewith GT; Machin D
    J R Coll Gen Pract; 1984 Apr; 34(261):239. PubMed ID: 6502561
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of prior information in the testing of new drugs.
    Allen DM
    Biometrics; 1971 Sep; 27(3):699-708. PubMed ID: 4940382
    [No Abstract]   [Full Text] [Related]  

  • 6. [2 treatments with about equal likelihood of a favorable outcome?].
    Rümke CL
    Ned Tijdschr Geneeskd; 1982 Mar; 126(12):529-31. PubMed ID: 7070547
    [No Abstract]   [Full Text] [Related]  

  • 7. [Principles of selection of control groups in clinical and prophylactic trials].
    Magnus K
    Nord Med; 1969 Nov; 82(47):1465-70. PubMed ID: 4903456
    [No Abstract]   [Full Text] [Related]  

  • 8. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal crossover designs in the presence of carryover effects.
    Laska E; Meisner M; Kushner HB
    Biometrics; 1983 Dec; 39(4):1087-91. PubMed ID: 6671121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experiment and therapy].
    Modr Z; Smahel O
    Cas Lek Cesk; 1965 Dec; 104(49):1345-50. PubMed ID: 5323070
    [No Abstract]   [Full Text] [Related]  

  • 11. Robust Bayesian sample size determination in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncertainty about clinical equipoise. There is another exchange on equipoise and uncertainty.
    Sackett DL
    BMJ; 2001 Mar; 322(7289):795-6. PubMed ID: 11282879
    [No Abstract]   [Full Text] [Related]  

  • 13. Uncertainty about clinical equipoise. Equipose and uncertainty principle are not mutually exclusive.
    Lilford RJ; Djulbegovic B
    BMJ; 2001 Mar; 322(7289):795. PubMed ID: 11322146
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical cases, trials, and the problem of the colored socks. Or the problem of induction in medicine].
    Terlizzi R
    Ital Heart J Suppl; 2000 Aug; 1(8):1052-4. PubMed ID: 10993014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crossover experiment for clinical trials.
    Brown BW
    Biometrics; 1980 Mar; 36(1):69-79. PubMed ID: 7370374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early stopping for sequential restricted tests of binomial distributions.
    Dambrosia JM; Greenhouse SW
    Biometrics; 1983 Sep; 39(3):695-710. PubMed ID: 6652203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing differential drug effect.
    Berry DA; Eaton ML; Ekholm BP; Fox TL
    Biometrics; 1984 Dec; 40(4):1109-15. PubMed ID: 6398711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.